SUPPLEMENT APPROVAL

AbbVie, Inc.
1 North Waukegan Road
Dept. PA77/Bldg. AP30
North Chicago, IL  60064

Attention:  Patti Neall
Associate Director, Regulatory Affairs

Dear Ms. Neall:

We have received your Supplemental New Drug Applications (sNDA) submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

<table>
<thead>
<tr>
<th>Application</th>
<th>Drug Product</th>
<th>Submitted on:</th>
<th>Received on:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 018082/S-048</td>
<td>Depakene (valproic acid) Oral Solution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 018723/S-057</td>
<td>Depakote (divalproex sodium) Delayed Release Tablets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 019680/S-044</td>
<td>Depakote Sprinkle Capsules</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 020593/S-035</td>
<td>Depacon (valproate sodium) Injection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 021168/S-035</td>
<td>Depakote ER (divalproex sodium) Extended Release Tablets</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

These supplemental applications provide for the addition of new safety language to the following section of the prescribing information:

Section 7.2 Effects of Valproate on Other Drugs

Drugs for which a potentially important valproate interaction has been observed
Addition of following:

*Propofol*

The concomitant use of valproate and propofol may lead to increased blood levels of propofol. Reduce the dose of propofol when co-administering with valproate. Monitor patients closely for signs of increased sedation or cardiorespiratory depression.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. The applications are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submissions, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Cathy Michaloski, Sr. Regulatory Project Manager, at (301) 796-1123.

Sincerely,

{See appended electronic signature page}

Eric P. Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
11/02/2016